Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: canagliflozin


Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

December 3rd 2020

Model results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England (Diabetes Therapy)

Categories: News, Treatment
Tags: canagliflozin, DKD, Type 2 Diabetes

Categories: Treatment
Tags: canagliflozin, DKD, Type 2 Diabetes

Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review

May 13th 2020

Overall, the CREDENCE trial demonstrated that canagliflozin improves renal outcomes and slows early disease progression in people with DKD (Diabetes Therapy)

Categories: Nephropathy, News
Tags: canagliflozin

Categories: Nephropathy
Tags: canagliflozin

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8)

September 17th 2019

Once-weekly semaglutide 1·0 mg was superior to daily canagliflozin 300 mg in reducing HbA 1c and bodyweight in patients with type 2 diabetes uncontrolled on metformin therapy. These outcomes might guide treatment intensification choices (The Lancet Diabetes & Endocrinology)

Categories: News
Tags: canagliflozin, semaglutide, Type 2 Diabetes

Categories:
Tags: canagliflozin, semaglutide, Type 2 Diabetes

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

August 28th 2019

Canagliflozin treatment led to an improvement in erythropoiesis in patients with impaired kidney function. The effect on erythropoiesis appeared to be due to an EPO production-mediated mechanism and might be independent of glycemic control; however, further studies are needed to clarify this since the present study had a small sample size and no comparator group (Diabetes Technology and Therapeutics)

Categories: Nephropathy, News
Tags: canagliflozin, erythropoiesis

Categories: Nephropathy
Tags: canagliflozin, erythropoiesis

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

June 12th 2019

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years (NEJM)

Categories: Nephropathy, News
Tags: canagliflozin, Type 2 Diabetes

Categories: Nephropathy
Tags: canagliflozin, Type 2 Diabetes

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

April 15th 2019

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years (NEJM)

Categories: Nephropathy, News
Tags: canagliflozin, Type 2 Diabetes

Categories: Nephropathy
Tags: canagliflozin, Type 2 Diabetes

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study

January 2nd 2019

In this study of middle-aged patients with type 2 diabetes and relatively low fracture risk, canagliflozin was not associated with increased risk for fracture compared with GLP-1 agonists (Annals of Internal Medicine)

Categories: Medication, News
Tags: canagliflozin, GLP1, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, GLP1, Type 2 Diabetes

Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK

September 25th 2017

This analysis suggests that, in the UK, canagliflozin 300 mg provides the best value for money among all SGLT2 inhibitors in terms of achieving HbA1c <7.0% when used as part of triple therapy with metformin plus sulfonylurea (Diabetes Therapy)

Categories: Medication, News
Tags: canagliflozin, SGLT2 inhibitors, Type 2 Diabetes, UK

Categories: Medication
Tags: canagliflozin, SGLT2 inhibitors, Type 2 Diabetes, UK

Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus

August 2nd 2017

The combined therapy of SGLT2 inhibitor along with metformin is more effective in HbA1c reduction and weight reduction as compared to monotherapy using metformin alone. Among the three SGLT2 inhibitors such as dapagliflozin canagliflozin and empagliflozin do not differ much in the efficiency of weight reduction. However, Empagliflozin 25mg is effective in HbA1c reduction (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: canagliflozin, dapagliflozin, dual therapy, Empagliflozin, insulin, SGLT2, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, dapagliflozin, dual therapy, Empagliflozin, insulin, SGLT2, Type 2 Diabetes

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

June 12th 2017

In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal (NEJM)

Categories: Cardiovascular, Medication, News
Tags: canagliflozin, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: canagliflozin, Type 2 Diabetes

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

February 28th 2017

Canagliflozin improved all three cardiovascular physiologic markers, consistent with the hypothesis that canagliflozin may have beneficial effects on some cardiovascular outcomes in patients with T2DM (Cardiovascular Diabetology)

Categories: Medication, News
Tags: canagliflozin, sodium glucose co-transporter 2 inhibitor

Categories: Medication
Tags: canagliflozin, sodium glucose co-transporter 2 inhibitor

Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors

December 1st 2016

Our study found that canagliflozin, dapagliflozin, and empagliflozin were associated with significantly increased risk of genital infections compared with placebo and other active treatments. Only dapagliflozin had dose–response relationship with UTIs and genital infections (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: canagliflozin, dapagliflozin, Empagliflozin, sodium-glucose cotransporter 2 inhibitors, Type 2 Diabetes, UTI

Categories: Medication
Tags: canagliflozin, dapagliflozin, Empagliflozin, sodium-glucose cotransporter 2 inhibitors, Type 2 Diabetes, UTI

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin

March 16th 2016

More patients treated with canagliflozin experienced reductions in both HbA1c and body weight compared with glimepiride for up to 104 weeks. Canagliflozin was generally well tolerated in patients with T2DM when used in combination with metformin (Diabetes Therapy)

Categories: Medication, News
Tags: canagliflozin, glimepiride, HbA1c, metformin, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, glimepiride, HbA1c, metformin, Type 2 Diabetes

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

October 12th 2015

In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: canagliflozin, incretin, SGLT2

Categories: Medication
Tags: canagliflozin, incretin, SGLT2

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

July 25th 2015

DKA and related events occurred at a low frequency in the canagliflozin type 2 diabetes program, with an incidence consistent with limited existing observational data in the general population with type 2 diabetes (Diabetes Care)

Categories: Medication, News
Tags: canagliflozin, DKA, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, DKA, Type 2 Diabetes

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskAstraZenecaSanofi DiabetesNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership